denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Education Program
Session: Beyond TTP: “Atypical” TMAs for the Hematologist
Hematology Disease Topics & Pathways:
Research, Bleeding and Clotting, Antibody Therapy, Clinical Practice (Health Services and Quality), Clinical Research, Thromboembolism, Diseases, Therapy sequence, Treatment Considerations, Biological therapies, Clinical procedures, Registries, Adverse Events, Technology and Procedures, Study Population, Human
Session: Beyond TTP: “Atypical” TMAs for the Hematologist
Hematology Disease Topics & Pathways:
Research, Bleeding and Clotting, Antibody Therapy, Clinical Practice (Health Services and Quality), Clinical Research, Thromboembolism, Diseases, Therapy sequence, Treatment Considerations, Biological therapies, Clinical procedures, Registries, Adverse Events, Technology and Procedures, Study Population, Human
Saturday, December 7, 2024, 2:00 PM-3:15 PM
Disclosures: Crowther: Bayer: Membership on an entity's Board of Directors or advisory committees; Eversana: Membership on an entity's Board of Directors or advisory committees; Astra Zeneca: Speakers Bureau; Pfizer: Speakers Bureau.
OffLabel Disclosure: There are no therapies specifically approved for CAPS so essentially everything I discuss will be off label.
<< Previous Presentation
|
Next Presentation